CULLINAN THERAPEUTICS RECEIVES U.S. FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CLN-978 ADMINISTERED SUBCUTANEOUSLY IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS

Reuters · 10/16 11:00

Please log in to view news